This article is part of the supplement: Ubiquitin-Proteasome System in Disease Part 1
Review
Patented small molecule inhibitors in the ubiquitin proteasome system
Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France
BMC Biochemistry 2007, 8(Suppl 1):S14 doi:10.1186/1471-2091-8-S1-S14
Published: 22 November 2007Abstract
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade® (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com webcite).
